Clinical Trials
56 trialsSTART: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Valo Therapeutics Oy
Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
Tcelltech Inc.
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
Lantheus Medical Imaging
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
Hansoh BioMedical R&D Company
A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
CabOSTar
Ipsen
CLOVER-2
Cellectar Biosciences, Inc.
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
SPEARHEAD-3 Pediatric Study
USWM, LLC (dba US WorldMeds)
A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
Ricoh USA, Inc.
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
GlaxoSmithKline
VARTUTRACE
Var2 Pharmaceuticals
TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
GlaxoSmithKline
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
MedPacto, Inc.
OST-164-01
Emerald Clinical Inc.
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
Hansoh BioMedical R&D Company
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
Hansoh BioMedical R&D Company
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
Eisai Inc.
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Hutchmed
IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Cellestia Biotech AG
Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Y-mAbs Therapeutics
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors
Shanghai Yunying Medical Technology
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
Bayer
Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma
Base Therapeutics (Shanghai) Co., Ltd.
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
Y-mAbs Therapeutics
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
Eisai Inc.
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors
Shanghai Yunying Medical Technology
IBI188 Combination Therapy in Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
MacroGenics
A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma
AlaMab Therapeutics (Shanghai) Inc.
Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
Emerald Clinical Inc.
Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.
Isofol Medical AB
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Celgene
Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma
Eleison Pharmaceuticals LLC.
A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma
Lee's Pharmaceutical Limited
A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)
Merck Sharp & Dohme LLC
Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
Insmed Incorporated
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
SillaJen, Inc.
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Merck Sharp & Dohme LLC
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
Oncolytics Biotech